

Anti-CUEDC2 Antibody (4L751)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	4L751
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Human CUEDC2 expression on SHSY5Y cells. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human CUEDC2, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	FCM: 1:25-1:100

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human CUEDC2 Protein
Antigen Species:	Human
Synonyms:	bA18I14.5;CUEDC 2;C10orf66;MGC2491;HOYS6

Research Background

CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IκB kinase alpha (IKKalpha) and IKKbeta and has an inhibitory role in the activation of transcription factor nuclear factor-kappaB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-alpha and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. The expression level of CUEDC2 has an inverse correlation with imatinib resistance and activity of NF-kappaB signaling pathway in CML cells, CUEDC2 could regulate imatinib sensitivity in CML cells at least partially through NF-kappaB signaling pathway. CUEDC2 may be a promising biomarker to evaluate the progression of serous ovarian carcinoma and to predict likely relapse of ovarian serous carcinoma. The decreased expression of CUEDC2 contributes to tumor growth in lung adenocarcinoma, leading to a poor clinical outcome.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481